- $3.47m
- $13.19m
- $3.42m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.95 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -899.53% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 3.5 | 4.21 | 4.31 | 2.61 | 3.42 | 2.6 | n/a | 3.02% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
OpGen, Inc. (OpGen) is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company, through its subsidiaries, is focused on developing and commercializing molecular microbiology solutions helping to guide clinicians with actionable information infections caused by multidrug-resistant microorganisms (MDROs). The Company’s product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, next-generation sequencing (NGS) technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well as the Curetis CE- in vitro diagnostics (IVD)-marked polymerase chain reaction (PCR)-based severe acute respiratory syndrome (SARS)-CoV-2 test kit. The Company’s subsidiaries include Curetis GmbH and Ares Genetics GmbH.
Directors
- William Rhodes NEC (67)
- Oliver Schacht CEO (50)
- Albert Weber CFO (54)
- Johannes Bacher COO (52)
- Mario Crovetto IND (67)
- R. Donald Elsey IND (67)
- Prabhavathi Fernandes IND (73)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 22nd, 2001
- Public Since
- May 5th, 2015
- No. of Shareholders
- 18
- No. of Employees
- 100
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 1,343,739
- Address
- 9717 Key West Avenue, Suite 100, ROCKVILLE, 20850
- Web
- https://opgen.com/
- Phone
- +1 3018699683
- Auditors
- CohnReznick LLP
Upcoming Events for OPGN
Q2 2024 OpGen Inc Earnings Release
Q3 2024 OpGen Inc Earnings Release
Similar to OPGN
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the OpGen share price?
As of Today at 22:30 UTC, shares in OpGen are trading at $2.41. This share price information is delayed by 15 minutes.
How has the OpGen share price performed this year?
Shares in OpGen last closed at $2.41 and the price had moved by -61.13% over the past 365 days. In terms of relative price strength the OpGen share price has underperformed the S&P500 Index by -69.07% over the past year.
What are the analyst and broker recommendations for OpGen?
The overall consensus recommendation for OpGen is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the OpGen dividend yield?
OpGen does not currently pay a dividend.
Does OpGen pay a dividend?
OpGen does not currently pay a dividend.
When does OpGen next pay dividends?
OpGen does not currently pay a dividend.
How do I buy OpGen shares?
To buy shares in OpGen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of OpGen?
As of the previous close price of $2.41, shares in OpGen had a market capitalisation of $3.24m.
Where are OpGen shares listed?
Here are the trading details for OpGen:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: OPGN
What kind of share is OpGen?
Based on an overall assessment of its quality, value and momentum OpGen is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a OpGen share price forecast for 2024?
The analyst consensus target price for shares in OpGen is $3.00. That is 24.48% above the last closing price of $2.41.
Analysts covering OpGen currently have a consensus Earnings Per Share (EPS) forecast of -$0.29 for the next financial year.
What is the trend in the OpGen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like OpGen. Over the past six months, its share price has underperformed the S&P500 Index by -51.04%.
As of the last closing price of $2.41, shares in OpGen were trading -46.99% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the OpGen PE Ratio?
The OpGen PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.41.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of OpGen?
OpGen's management team is headed by:
- William Rhodes - NEC
- Oliver Schacht - CEO
- Albert Weber - CFO
- Johannes Bacher - COO
- Mario Crovetto - IND
- R. Donald Elsey - IND
- Prabhavathi Fernandes - IND